Abstract:
Artificial intelligence (“AI”) is transforming the pharmaceutical industry, significantly accelerating drug discovery. This article examines AI’s transformative role in early drug discovery and preclinical testing, highlighting its potential to expedite the development of novel therapies. The increasing integration of AI into drug discovery necessitates careful consideration of its implications for the established patent framework. With AI-driven innovation becoming more prevalent, ongoing discussions on contentious issues such as inventorship and patentability are crucial. This article explores these evolving patent considerations, providing a practitioner’s perspective on the intersection of AI and intellectual property in the pharmaceutical sector.